Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX raises 2025 EPS outlook to $11.93-$12.43 after 5% first-quarter EPS rise

Positive Impact 4 of 5 guidance Written later

IDEXX reported first-quarter 2025 revenue of $998 million, up 4% as reported and 5% organic, and diluted EPS of $2.96, up 5% as reported. The company raised its full-year 2025 revenue guidance to $4,095 million-$4,210 million and its EPS outlook to $11.93-$12.43, though part of the EPS gain came from a $0.08 litigation accrual adjustment.

Key points

  • Q1 2025 revenue was $998 million, up 4% as reported and 5% organic.
  • Diluted EPS was $2.96, up 5% as reported and 7% on a comparable basis, which excludes a $0.08 benefit from a discrete litigation expense accrual adjustment.
  • 2025 revenue guidance was raised to $4,095 million-$4,210 million from $4,055 million-$4,170 million; EPS outlook rose to $11.93-$12.43 from $11.74-$12.24.
  • Organic revenue growth guidance of 6%-9% was maintained.

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECMay 1, 2025, 6:30 AM ET
Accession number0001104659-25-042955

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.